GlucoTrack Inc (GCTK NASDAQ) stock market data APIs
$0.8042
0.04(5%)
as of May 8, 2026
Try our APIs with
free plan!
GlucoTrack Inc Financial Data Overview
Price chart is built with
Anychart
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.
Prev. Close
0.8042
Open
0.841
High
0.849
Low
0.7542
52 wk Range
0.619-14.14
Market Cap
2 929 K
Shares Outstanding
3 659 K
EPS
-4.64
Beta
0.773
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GlucoTrack Inc data using free add-ons & libraries
Get GlucoTrack Inc Fundamental Data
GlucoTrack Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 048 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GlucoTrack Inc News
New
Glucotrack Submits Blood Glucose Monitoring Technology to FDA
By Daniella Parra Glucotrack, Inc. (Nasdaq: GCTK) said it has submitted an Investigational Device Exemption application to the FDA to begin a U.S. clinical study for its fully implantable continuous ...
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and comme...
Study Supports GlucoTrack’s Blood Glucose Monitoring Implant
By Karen Roman GlucoTrack, Inc. (Nasdaq: GCTK) said a peer-reviewed study published in the Institute of Electrical and Electronics Engineers Sensors Journal supported the feasibility of long-life imp...
Glucotrack FY25 Net Loss Narrows; Plans To Submit An IDE For CBGM In Q2 2026
(RTTNews) - Glucotrack, Inc. (GCTK), a medical technology company, reported financial results for the full year ended December 31, 2025, reflecting a narrower net loss. In addition, the firm provided ...
Get GlucoTrack Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
